BioNTech Investor Day Presentation Deck

BNT221 Phase 1 trial in patients with PD-1-refractory metastatic melanoma Unresectable or metastatic melanoma Progression on anti-PD-1 Received anti CTLA-4 Key endpoints Cohort A Dose escalation (3x3) Safety Clinical activity (ORR, response durability) Immune monitoring Cell viability Velez D, et al. SITC Annual Meeting 2021, Poster presentation 201; Clinical Trials.gov: NCT04625205. Selected dose -- H Unresectable or metastatic melanoma Stable or asymptomatic progression on anti-PD-1 ± anti CTLA-4 Status Recruiting Up to 20 patients will be treated in the dose-expansion Cohort B Cell therapies Cohort B Dose expansion BIONTECH 140

View entire presentation